NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories declared that its board has initiated a stock buyback plan on Wednesday, February 12th 2020, which authorizes the company to repurchase 5,000,000 outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Friday, January, 31st. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.13. The company earned $605.50 million during the quarter, compared to analysts' expectations of $600.60 million. IDEXX Laboratories had a net margin of 17.77% and a return on equity of 283.27%. The business's revenue was up 10.2% on a year-over-year basis. During the same period last year, the company earned $0.98 EPS. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories updated its FY20 earnings guidance on Friday, January, 31st. The company provided EPS guidance of $5.42-5.58 for the period, compared to the Thomson Reuters consensus estimate of $5.41. The company issued revenue guidance of $2.62-2.66 billion, compared to the consensus revenue estimate of $2.63 billion.

6 Wall Street analysts have issued 1-year price targets for IDEXX Laboratories' shares. Their forecasts range from $277.00 to $310.00. On average, they anticipate IDEXX Laboratories' share price to reach $293.33 in the next twelve months. This suggests a possible upside of 0.8% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Headlines about IDXX stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. IDEXX Laboratories earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for IDEXX Laboratories.

IDEXX Laboratories saw a drop in short interest in January. As of January 31st, there was short interest totalling 1,210,000 shares, a drop of 6.9% from the January 15th total of 1,300,000 shares. Based on an average daily trading volume, of 507,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 1.4% of the shares of the company are short sold. View IDEXX Laboratories' Current Options Chain.

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Netflix (NFLX), Alibaba Group (BABA), Adobe (ADBE), Mastercard (MA), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and Walt Disney (DIS).

IDEXX Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.40%), Bamco Inc. NY (4.39%), Blair William & Co. IL (1.80%), Principal Financial Group Inc. (1.39%), Capital World Investors (1.28%) and Franklin Resources Inc. (1.19%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Skandinaviska Enskilda Banken AB publ , Bamco Inc. NY, Massachusetts Financial Services Co. MA, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was bought by a variety of institutional investors in the last quarter, including KBC Group NV, Robeco Institutional Asset Management B.V., Beacon Investment Advisory Services Inc., State Street Corp, Credit Suisse AG, Bank of Montreal Can, Great Diamond Partners LLC and Duality Advisers LP. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $290.97.

IDEXX Laboratories has a market capitalization of $24.83 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

The official website for IDEXX Laboratories is http://www.idexx.com/.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]